[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo
DS-8201: BLA submission for HER2 positive metastatic breast cancer previously treated with T-DM1 (based on DESTINY-Breast01 trial) in H1 FY2019 (Daiichi Sankyo) - Jun 13, 2019 - ASCO 2019: NDA submission in Japan for HER2 positive gastric cancer (based on DESTINY-Gastric01 trial) in H1 FY2020 
BLA • Japanese regulatory
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/detail/005443.html
 
Jun 13, 2019
 
 
1c1a78ca-77b1-43c4-9e09-38e8bb73a721.jpg